Janux Therapeutics (NASDAQ:JANX) CEO David Alan Campbell Sells 8,072 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 8,072 shares of the stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $110,828.56. Following the completion of the sale, the chief executive officer owned 284,982 shares of the company’s stock, valued at approximately $3,912,802.86. The trade was a 2.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock opened at $13.65 on Friday. The stock’s 50 day simple moving average is $22.51 and its 200-day simple moving average is $23.74. The stock has a market cap of $821.05 million, a P/E ratio of -8.13 and a beta of 2.88. Janux Therapeutics, Inc. has a 1-year low of $13.52 and a 1-year high of $61.59.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.21. The company had revenue of $10.00 million during the quarter, compared to analyst estimates of $3.07 million. As a group, research analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Key Stores Impacting Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

• Negative Sentiment: CEO David Alan Campbell sold 8,072 shares (~$110,829); he still holds 284,982 shares. Form 4 – Campbell
• Negative Sentiment: Insider Thomas Diraimondo sold 2,505 shares (~$34,394); remaining position ~124,425 shares. Form 4 – Diraimondo
• Negative Sentiment: Zachariah McIver sold 2,714 shares (~$37,263); post-sale holding ~23,286 shares. Form 4 – McIver
• Negative Sentiment: VP Maria Dobek sold 1,462 shares (~$20,073); holds ~15,373 shares after the sale. Form 4 – Dobek
• Negative Sentiment: Insider Charles M. Winter sold 2,401 shares (~$32,966); remaining holding ~77,721 shares. Form 4 – Winter

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in JANX. California State Teachers Retirement System raised its holdings in shares of Janux Therapeutics by 1.1% in the 2nd quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock valued at $858,000 after buying an additional 404 shares during the period. ProShare Advisors LLC grew its position in Janux Therapeutics by 8.1% in the 2nd quarter. ProShare Advisors LLC now owns 10,284 shares of the company’s stock valued at $238,000 after acquiring an additional 771 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in Janux Therapeutics by 25.6% during the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock worth $93,000 after purchasing an additional 820 shares during the period. Virtus Investment Advisers LLC lifted its position in shares of Janux Therapeutics by 37.9% during the second quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after purchasing an additional 1,011 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its position in shares of Janux Therapeutics by 7.9% during the first quarter. MetLife Investment Management LLC now owns 18,663 shares of the company’s stock worth $504,000 after purchasing an additional 1,365 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on JANX shares. Bank of America reduced their price target on Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Stifel Nicolaus reduced their target price on shares of Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday, December 2nd. Truist Financial started coverage on shares of Janux Therapeutics in a research note on Wednesday, September 10th. They issued a “buy” rating and a $100.00 price target for the company. Cantor Fitzgerald reduced their price target on shares of Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 2nd. Finally, Wedbush reiterated an “outperform” rating and issued a $45.00 price objective (down from $76.00) on shares of Janux Therapeutics in a report on Tuesday, December 2nd. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Janux Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $61.08.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.